International Assets Investment Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

International Assets Investment Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-385	Closed	-$35K	–	1241
2023 Q1	$35K	Buy	+385	New	+$22.6K	0.01%	731

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

International Assets Investment Management's RETA Position: Q2 2023 in Review

International Assets Investment Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 385 shares — an estimated $35K sold.

International Assets Investment Management first reported a position in RETA in Q1 2023 and held it in 1 quarter. The position peaked at $35K in Q1 2023. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

International Assets Investment Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
International Assets Investment Management sold 385 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $35K.
International Assets Investment Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2023 and held it in 1 quarter.
International Assets Investment Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $35K in Q1 2023.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on International Assets Investment Management's 13F filing for Q2 2023, filed 20 Jul 2023.